PYXS Stock — Pyxis Oncology Inc.: Cash, EV, Pipeline

Share price

$3.33

Market cap

$277.7M

Cash

$33.0M

Enterprise value

$244.7M

Balance sheet

Cash	$33.0M
Debt	$0.0M
Net cash	$33.0M
Enterprise value	$244.7M
Basic shares	103.0M shares
Fully diluted shares	144.5M shares
Fully diluted market cap	$481.1M
Cash per share	$0.32

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PYXS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 6 - Jul 18	PYX-201	Phase 1	Solid Tumor; Advanced Solid Tumor	—
Jan 17 - Feb 28	PYX-201	Phase 2	Advanced Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MICVO

Phase 2 · Active Modality: antibody-drug conjugate

Aliases micvotabart pelidotin, PYX-201

Target EDB+ fibronectin

Partnerships Pfizer: license to ADC targets and the Flexible Antibody Conjugation Technology (FACT) Platform. Merck & Co: Clinical Trial Collaboration and Supply Agreement (Nov 2024) for MICVO in combination with KEYTRUDA

Indications

Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) (Phase 2)

Status note Lead product candidate; investigational ADC targeting the EDB+ splice variant of fibronectin. Phase 1/2 study (PYX-201-102) in combination with KEYTRUDA (pembrolizumab) in R/M HNSCC, actively enrolling and dosing; FDA Fast Track designation for monotherapy in R/M HNSCC progressing after platinum-based chemotherapy and anti-PD-(L)1 therapy.

PYX-106

Stage not disclosed · Active Modality: monoclonal antibody

Aliases BSI-060T

Target Siglec-15

Indications

Solid tumors (immuno-oncology) (Stage not disclosed)

Status note Siglec-15 targeting IO antibody; clinical development paused in December 2024.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PYX-201
Lead indication	Advanced Solid Tumors
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06795412	Phase 2	Recruiting	Sponsor	PYXS	MRK	Advanced Solid Tumors	—
NCT05720117	Phase 1	Recruiting	Sponsor	PYXS	—	Solid Tumor; Advanced Solid Tumor	—
NCT05718557	Phase 1	Active, not recruiting	Sponsor	PYXS	—	Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Pyxis Oncology, Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PYXS — Pyxis Oncology Inc.